Wellthy Therapeutics to enable 10 million patients to reverse, prevent or control chronic conditions by 2030

Yash Ved, MumbaiWednesday, May 12, 2021, 08:00 Hrs  [IST]

Wellthy Therapeutics, a leading digital therapeutics (DTx) company, has initiated several measures to inspire and enable 10 million patients to reverse, prevent or control their chronic conditions by 2030.

For this mission, the company is strongly aligned with the Digital Health Mission initiatives as the company helps tshe government and private insurers to reduce the cost of healthcare and improve health outcomes in the real world.

“Our platforms empower our partners to capture real world data from patients and draw meaningful insights and trends from patient longitudinal data. For hospitalized patients, we provide effective rehabilitation and bring down healthcare costs with reduced readmissions and hospital visits. We are also solving for interoperability amongst the broader healthcare stack for easy access of care across India,” stated Abhishek Shah, CEO & co-founder, Wellthy Therapeutics.

Wellthy Therapeutics proprietary platform, Wellthy Care, helps to prevent, manage or treat complex clinical conditions. It works closely with pharmaceutical companies, medical device manufacturers, Insurers (payors), and health (hospital) systems to design and deploy clinically validated digital therapeutic solutions to achieve real-world clinical and business outcomes across multiple therapeutic areas.

The platform works to deliver outcome, adherence and risk reduction solutions, all with the patient/end user at the centre.

"Wellthy Therapeutics augments the traditional model of care where doctor-patient touch points are limited to 2-3 physician visits to a continuous care model. Our DTx platform ensures clinical evidence backed continuity of care and provides for unmet medical needs, thus helping patients with on demand access and also ensure clinicians can track their patient progress with continuous digital touchpoints and provide just in time interventions,” Shah added.
Shah stated that post Covid-19 healthcare is digitizing at an enormous pace and DTx interventions are going to be significant drivers of it. Regulatory and reimbursement policies are still evolving globally. Government and Global regulatory bodies are working towards setting standards for clinical trials and efficacy of DTx Solutions.

“As commercialization of Digital Therapeutics starts taking shape, DTx will become an integral piece of all healthcare systems in the future and episodic care will phase out. At Wellthy Therapeutics, we are confident that our clinical evidence backed digital therapies will significantly contribute to the new era of digital healthcare,” added Shah.

Wellthy Therapeutics is a leading digital therapeutics company working across Europe and Asia to bridge the gap for better health outcomes, by enabling digital care for complex clinical conditions.